ChinaDrugStatus

Trastuzumab deruxtecan

德曲妥珠单抗
Brand: Enhertu / 优赫得·Oncology·Last verified 2026-11-20

HER2-directed ADC whose 2026 NRDL payment scope expands from 2 breast cancer settings to 7 indications across breast, gastric/GEJ, and HER2-mutant NSCLC.

China Approval (NMPA)

Pending Verification

Reimbursement catalog entries for this drug are verified from NHSA official PDFs. Individual NMPA registration certificate numbers (国药准字) and approval dates are queued for incremental verification.

Verify directly on NMPA Portal ↗

National Reimbursement

Announced · Effective Jan 1, 2027
2026 Edition Entry
Negotiated #255 · Class B
Agreement Period
2027-01-01 to 2028-12-31
Payment Standard
* Confidential (marked with asterisk in NHSA PDF)
2026 Payment Scope
Expanded to 7 indications: (1) ≥2L HER2+ mBC; (2) HER2-low mBC; (3) HR+ HER2-low/ultralow mBC post-ET; (4) Neoadjuvant HER2+ stage II high-risk/III BC seq. THP; (5) ≥3L HER2+ gastric/GEJ; (6) ≥2L HER2+ gastric/GEJ post-trastuzumab; (7) ≥2L HER2 (ERBB2)-mutant NSCLC.
限:1.HER2阳性不可切除/转移性乳腺癌(≥1线抗HER2后);2.HER2低表达不可切除/转移性乳腺癌(化疗后);3.HR阳性HER2低表达或HER2超低表达(IHC 0伴细胞膜染色)乳腺癌(内分泌治疗进展后单药);4.序贯THP用于HER2阳性Ⅱ期(高危)或Ⅲ期乳腺癌新辅助治疗;5.HER2阳性局部晚期/转移性胃或GEJ腺癌(≥2线后);6.HER2阳性局部晚期/转移性胃或GEJ腺癌(≥1线含曲妥珠单抗方案后);7.HER2(ERBB2)激活突变不可切除/转移性NSCLC(≥1线系统治疗后)。

Commercial Insurance List

Not Listed

Not listed in the 2025 or 2026 NHSA Commercial Health Insurance Innovative Drug List.

2025 vs 2026 NRDL Payment Scope Comparison

2025 NRDL · #228NHSA · PDF p.157

Restricted to 2 breast cancer settings: (1) Unresectable/metastatic HER2+ breast cancer after ≥1 prior anti-HER2 therapy; (2) Unresectable/metastatic HER2-low (IHC 1+ or 2+/ISH-) breast cancer after prior systemic therapy or ≤6-month adjuvant recurrence.

限:1.既往接受过一种或一种以上抗HER2药物治疗的不可切除或转移性HER2阳性成人乳腺癌患者;2.既往在转移性疾病阶段接受过至少一种系统治疗的,或在辅助化疗期间或完成辅助化疗之后6个月内复发的,不可切除或转移性HER2低表达(IHC 1+或IHC 2+/ISH-)成人乳腺癌患者。

2026 NRDL · #255NHSA · PDF p.142

Expanded to 7 indications: (1) ≥2L HER2+ mBC; (2) HER2-low mBC; (3) HR+ HER2-low/ultralow mBC post-ET; (4) Neoadjuvant HER2+ stage II high-risk/III BC seq. THP; (5) ≥3L HER2+ gastric/GEJ; (6) ≥2L HER2+ gastric/GEJ post-trastuzumab; (7) ≥2L HER2 (ERBB2)-mutant NSCLC.

限:1.HER2阳性不可切除/转移性乳腺癌(≥1线抗HER2后);2.HER2低表达不可切除/转移性乳腺癌(化疗后);3.HR阳性HER2低表达或HER2超低表达(IHC 0伴细胞膜染色)乳腺癌(内分泌治疗进展后单药);4.序贯THP用于HER2阳性Ⅱ期(高危)或Ⅲ期乳腺癌新辅助治疗;5.HER2阳性局部晚期/转移性胃或GEJ腺癌(≥2线后);6.HER2阳性局部晚期/转移性胃或GEJ腺癌(≥1线含曲妥珠单抗方案后);7.HER2(ERBB2)激活突变不可切除/转移性NSCLC(≥1线系统治疗后)。

Approved Products, Dosage Forms & Approval Numbers

0 verified NMPA records
Individual NMPA approval numbers (国药准字) and dosage strength rows have not yet been manually backfilled for this drug in our launch sample. Check the NMPA Drug Database Portal ↗ or request priority backfill.

Change Timeline

  1. (2027-01-01)Basic NRDL· Catalog published: Nov 14, 2026

    2026 NRDL · Payment Scope Updated

    Expanded from 2 breast cancer settings in 2025 (#228) to 7 indications in 2026 (#255), adding HR+ HER2-low/ultralow BC, neoadjuvant HER2+ BC, 2L/3L+ HER2+ gastric/GEJ, and HER2-mutant NSCLC.

    Chinese original: 支付范围由2025版2项扩增至7项,新增HR+ HER2低/超低表达乳腺癌、HER2+乳腺癌新辅助、HER2+胃/GEJ腺癌(二线及三线以上)及HER2突变NSCLC。

    NHSA · PDF p.142Verified 2026-11-20

Verified Names & Aliases

Every English INN, Chinese generic name, brand name, and R&D code is recorded with its source.

注射用德曲妥珠单抗dosage name(NHSA)
T-DXdcode(WHO)
DS-8201code(WHO)
Enhertubrand en(WHO)
优赫得brand zh(NMPA)

Primary Sources for This Record